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Abstract: Health care-associated infections (HCAIs) are infections that occur while receiving 
health care, developed in a hospital or other health care facility that first appear 48 hours or more 
after hospital admission, or within 30 days after having received health care. Multiple studies 
indicate that the common types of adverse events affecting hospitalized patients are adverse 
drug events, HCAIs, and surgical complications. The US Center for Disease Control and Pre-
vention identifies that nearly 1.7 million hospitalized patients annually acquire HCAIs while 
being treated for other health issues and that more than 98,000 patients (one in 17) die due to 
these. Several studies suggest that simple infection-control procedures such as cleaning hands 
with an alcohol-based hand rub can help prevent HCAIs and save lives, reduce morbidity, and 
minimize health care costs. Routine educational interventions for health care professionals can 
help change their hand-washing practices to prevent the spread of infection. In support of this, 
the WHO has produced guidelines to promote hand-washing practices among member countries.
Keywords: health care-associated infections, central line-associated bloodstream infections, sur-
gical site infections, catheter-associated urinary tract infections, ventilator-associated pneumonia
Background
Health care-associated infections (HCAIs) are those infections that patients acquire 
while receiving health care.1 The term HCAIs initially referred to those infections linked 
with admission to an acute-care hospital (earlier called nosocomial infections), but 
the term now includes infections developed in various settings where patients obtain 
health care (eg, long-term care, family medicine clinics, home care, and ambulatory 
care). HCAIs are infections that first appear 48 hours or more after hospitalization or 
within 30 days after having received health care.2 Multiple studies indicate that the 
most common types of adverse events affecting hospitalized patients are adverse drug 
events, HCAIs, and surgical complications.3–7 The US Center for Disease Control and 
Prevention identifies that nearly 1.7 million hospitalized patients annually acquire 
HCAIs while being treated for other health issues and that more than 98,000 of these 
patients (one in 17) die due to HCAIs.8 The Agency for Health care Research and 
Quality reported that HCAIs are the most common complications of hospital care and 
one of the top 10 leading causes of death in the USA.9 Out of every 100 hospitalized 
patients, seven patients in advanced countries and ten patients in emerging countries 
acquire an HCAI.10 Other studies conducted in high-income countries found that 
5%–15% of the hospitalized patients acquire HCAIs which can affect from 9% to 
37% of those admitted to intensive care units (ICUs).11,12 Multiple research studies 
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report that in Europe hospital-wide prevalence rates of HCAIs 
range from 4.6% to 9.3%.13–21 The WHO reports however that 
HCAIs usually receive public attention only when there are 
epidemics.22 HCAIs also have impact on critically ill patients 
with around 0.5 million episodes of HCAIs being diagnosed 
every year in ICUs alone.7,14,23 ICU patients are often in a very 
critically ill, immuno-compromised status which increases 
their susceptibility to HCAIs.24,25
Brief history
There has been long-standing awareness that the practice of 
medicine can do harm as well as good. For example, Hip-
pocrates, the father of modern medicine, stated more than 
2,500 years ago that “I will use treatments for the benefit of 
the ill in accordance with my ability and my judgment, but 
from what is to their harm and injustice I will keep them.”26 
It was also recognized (eg, by Semmelweis discussing puer-
peral fever) many years ago that coming into hospitals (in 
particular) can be dangerous.27 In this century, the idea that 
medicine could cause harm, including death is described as 
“unintended physical injury resulting from or contributed to 
by medical care, including … [its] absence … that requires 
additional monitoring, treatment or hospitalization, or … 
results in death.”28,29 Offering another perspective, an Ameri-
can natural sciences writer noted that HCAIs are now killing 
around 100,000 people, many more than HIV/AIDS, cancer, 
or road traffic accidents.30
The Hungarian obstetrician Professor (Dr) Ignaz Phillip 
Semmelweis is largely considered as the medical doctor 
who realized that health care providers could communicate 
disease. His work identified the mode of communication 
and spread of puerperal sepsis while working at the Mater-
nity Hospital in Vienna. In 1847, he observed higher rates 
of maternal mortality among patients treated by obstetri-
cians and medical students than among those cared for by 
midwives. At that time, he also found that a pathologist had 
died of sepsis after wounding himself with a scalpel while 
carrying out an autopsy on a patient with puerperal sepsis. 
The pathologist’s illness mirrored that of women with puer-
peral sepsis, and Semmelweis wrote that both a scalpel and 
a physicians’ contaminated hands could transmit organisms 
to mothers during labor. He introduced chlorinated lime 
hand washing to the obstetric hospital staff, resulting in 
large improvements in maternal mortality rates.31 However, 
Semmelweis’ theories were dismissed by most of the medi-
cal establishment because of a lack of appropriate statistical 
analysis of the data. Nevertheless, after Koch’s postulates 
were published in 1890, the germ theory of disease and 
Semmelweis’ theory of transmission of disease from doctor 
to patient were found to be valid. Semmelweis was therefore 
the first to describe an HCAI and provide an intervention to 
avert its spread through hand hygiene.32
Prevalence and brief outline of 
HCAIs
A survey conducted in 183 US hospitals with 11,282 patients 
reported that 4% of patients had at least one HCAI with the 
most common microorganism being Clostridium difficile. 
Most infections were surgical site infections (SSIs), pneumo-
nia, and gastrointestinal infections.33 A study 2 years earlier 
by the same group found that 6% (51) of patients had suffered 
from HCAIs with the top 75.8% acquiring SSIs, urinary tract 
infections (UTIs), pneumonia, and bloodstream infections. 
Staphylococcus aureus was the most frequently detected 
microorganism.34 The group conducted a comparative study 
between 2011 and 2015 and found a statistically significant 
(P<0.05) reduction of HCAIs in SSIs, UTIs, and central line 
infections, probably due to a national initiative.35
HCAIs are also problematic elsewhere in the world. For 
example, a study in Singapore reported 11.9% (646) patients 
with HCAIs, primarily undetermined clinical sepsis, and 
pneumonia caused mainly by S. aureus and Pseudomonas 
aeruginosa.36 This study also reported that the Acinetobacter 
species and P. aeruginosa were extremely resistant to car-
bapenem.36 A recent European study found that 2,609,911 
new patients were identified as having HCAIs annually in 
the European Union and European Economic Area.37 This 
study revealed that for every 20 patients hospitalized, at least 
one acquired an HCAI which was preventable.37 Klebsiella 
pneumoniae and the Acinetobacter species were exceedingly 
resistant to multiple antimicrobials, and the lack of new anti-
microbials increases the huge burden in Europe.37 In Greece, 
the HCAI prevalence rate was 9.1%. The frequent types 
of HCAIs were lower respiratory tract infections (LRTIs), 
bloodstream infections, UTIs, SSIs, and systemic infections.38 
One systematic review and meta-analysis regarding HCAIs in 
Southeast Asian countries (Brunei, Myanmar, Cambodia, East 
Timor, Indonesia, Laos, Malaysia, the Philippines, Singapore, 
Thailand, and Vietnam) found an overall prevalence rate of 
9.1% with the most common microorganisms being P. aerugi-
nosa, the Klebsiella species, and Acinetobacter baumannii.39
A study conducted in eight university hospitals of Iran 
(ranging from 60 to 700 beds) reported an overall HCAI 
frequency of 9.4%, the most common HCAIs were blood-
stream infections, SSIs, UTIs, and pneumonia.40 A logistic 
regression analysis showed that the odds ratio (OR) for males 
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as opposed to females acquiring infections was 1.56 (95% 
confidence interval [CI] 1.21–2.02). Additional risk factors 
for HCAIs include a central intravascular catheter, adjusted 
OR of 3.86 (95% CI 2.38–6.26), and with a urinary catheter, 
adjusted OR of 3.06 (95% CI 2.19–4.28). Being admitted to 
an ICU is not in itself a self-determining HCAI risk factor. 
The OR for all HCAIs of acquiring an infection was 3.24 
(95% CI 2.34–4.47) in patients with hospital stays longer 
than 8 days.33 Seventy-one percentage (71%) of the studied 
patients received antimicrobials, but 9.4% had at least one 
evidence of infection.33 Another study revealed that the 
average number of microbes ranged from on (9.67×1011), 
working surfaces (1.64×1012), door handles (1.71×1012), 
and highest in taps (2.08×1012).41 The highest number (23) 
of pathogens were isolated from door handles, and the peak 
variance of pathogens were on hospital floors (7). Among 
those microbes, those that were disease-producing were 
46.14%, 53.86% were nonpathogenic, the most common was 
S. aureus at 14.42% and 45.2% of the total bacterial isolates 
comprised Bacillus subtilis. A study conducted in Ghana 
reported that gentamicin was the most effective antibiotic 
(100%) on both Gram-positive and Gram-negative organisms, 
but of the 12 antibiotics tested (ampicillin, cefuroxime, cotri-
moxazole, cefotaxime, tetracycline, amikacin, gentamicin, 
chloramphenicol, cefixime, cloxacillin, and erythromycin), 
six were resistant to either Gram-positive or Gram-negative 
organisms.41 Most of the HCAIs in the US are triggered by 
the ESKAPE group, comprising the antimicrobial-resistant 
Gram-negative microorganisms (K. pneumoniae, A. bauman-
nii, P. aeruginosa, and Enterobacter spp.) and the Gram-
positive species, Enterococcus faecium and S. aureus.42–44 
Multiple studies report that Gram-negative organisms are 
responsible for 10%,45 20%–40%,46 of HCAIs and that anti-
microbial resistance places a significant burden on the global 
health care system, particularly in low resource countries.47,48 
This problem is exacerbated as research and development 
into new antimicrobials targeting Gram-negative organisms 
has rapidly decreased in recent years.48
Among the newer aminoglycosides, plazomicin has 
been found to be active against the extended-spectrum beta-
lactamase (ESBL) generating strains of Enterobacter spp., 
Escherichia coli, and K. pneumoniae49 and more effective 
in laboratory experiments against A. baumannii than genta-
micin, tobramycin, and amikacin.50 Plazomicin has a better 
safety profile than other drugs, with no report of damage 
to the cochlea, auditory nerve, vestibular, and renal system 
in healthy volunteers, even with high and multiple doses.51 
Another study found that, in a comparison between HCAIs 
due to methicillin-sensitive S. aureus and methicillin-resistant 
S. aureus (MRSA), isolates were statistically significantly 
(P<0.005) more resistant to ciprofloxacin, clindamycin, 
trimethoprim/sulfamethoxazole, erythromycin, gentamicin, 
and tetracycline.52 Hospital waste, especially contaminated 
surgical waste, often acts as a reservoir for pathogenic viru-
lent microorganisms, and it suggested that 20%–25% of the 
waste produced by health care outlets is considered to have 
high potential to cause HCAIs, it therefore needs appropriate 
handling and disposal.53,54
Causative organisms
Around 12–17 microorganisms cause 80%–87% of HCAIs: 
S. aureus, Enterococcus species (eg, faecalis, faecium), E. 
coli, coagulase-negative Staphylococci, Candida species 
(eg, albicans, glabrata), K. pneumoniae and Klebsiella 
oxytoca, P. aeruginosa, A. baumannii, Enterobacter spe-
cies, Proteus species, Yeast NOS, Bacteroides species, and 
other pathogens.45,55,56 Among these pathogens, 16%–20% 
include multidrug-resistant (MDR) phenotypes: MRSA, 
vancomycin-resistant E. faecium, carbapenem-resistant 
P. aeruginosa, extended-spectrum cephalosporin-resistant 
K. pneumoniae, K. oxytoca, E. coli, and Enterobacter spe-
cies, and carbapenem-resistant P. aeruginosa, K. pneumoniae/ 
K. oxytoca, E. coli, Enterobacter species, and A. bauman-
nii.45,55 Some of these Gram-negative microorganisms have 
a much higher rate (20%–40%) of resistance than others45 
with the organisms isolated from device-associated HCAIs 
having the highest antimicrobial resistance phenotypes.56 In 
the latter study, although similar to the percentage resistance 
for most phenotypes was that in an earlier research study,45 an 
upsurge in the scale of the resistance fractions against E. coli 
pathogens was observed, especially with fluoroquinolones.56 
Acinetobacter, Burkholderia spp. and Pseudomonas spp. 
isolates were 100% were 92% resistant to cephalosporins 
respectively. Burkholderia spp. was again totally resistant to 
fluoroquinolones and Acinetobacter spp. and Pseudomonas 
spp. were 94.2% and 95.8% resistant, respectively. The same 
study reported that 86.4% Acinetobacter spp. and 62.5% 
Pseudomonas spp. showed a high resistance to carbapenems, 
the preferred drug regime in ICUs. Carbapenems were found 
more effective against Burkholderia spp. with 20% resistance.57 
In another study, Enterobacteriaceae community were found 
to be completely resistant to third-generation cephalosporins.58 
Over 80% of the Klebsiella spp. community were resistant 
to ciprofloxacin, gentamicin, piperacillin, tazobactam, and 
imipenem showing 48.6% resistance. E. coli was equally 
resistant although carbapenems were effective in almost 
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80% cases. Although Citrobacter spp.-related HCAIs are a 
relatively minor proportion, they also show resistance toward 
cephalosporins, fluoroquinolones, and aminoglycosides.58 
Another study reported that although the Acinetobacter spp. 
were 76.99%–92.01%, resistant to most antimicrobials, only 
30% of Acinetobacter spp. isolated were susceptible.59 It can 
be seen therefore that the causative pathogenic microorganisms 
differ from country to country as does patterns of resistance.
Types of HCAIs
Alongside infections due to cross-contamination between 
patients and health workers, patients being susceptible to 
common infections due to diminished immune responses, 
and infections at surgery sites (SSIs), many HCAIs are due 
to implants and prostheses. These include central line-associ-
ated bloodstream infections (CLABSIs), catheter-associated 
UTIs, and ventilator-associated pneumonia (VAP).57,60,61
CLABSIs
CLABSIs substantially increase morbidity, mortality, and 
health care costs, and great attention has been paid to 
addressing these.62,63 As a consequence, in 2009, 25,000 
fewer CLABSIs occurred in the ICUs of US hospitals than 
in 2001, a 58% reduction, with about 6,000 lives saved and 
estimated financial savings of US$414 million in potential 
excess health care costs, although the costs of reducing such 
infections is very high.64 It is estimated that it costs ~$1.8 
billion between 2001 and 2009 to save an additional 27,000 
lives.64 Despite this investment, a considerable number of 
CLABSIs still occur, especially in outpatient hemodialysis 
centers and inpatient wards.64 Another study also reported 
the link between CLABSIs and considerable morbidity and 
mortality, although there is a wide variation in reported infec-
tion rates (from 20% to 62.5%) in emerging economies.65 
A study conducted in Taiwan reported the occurrence of 
CLABSIs as 3.93 per 1,000 central-catheter days.66 The most 
common causative pathogens were Gram-negative (39.2%), 
Gram-positive (33.2%), and Candida spp. microorganisms 
(27.6%).66 In this study, patients developed CLABSIs 8 days 
from the time of insertion of the central line catheter.66 Mul-
tivariate analysis showed that a higher Pitt bacteremia score 
(OR 1.41; 95% Cl=1.18–1.68) and the prolonged interval 
between the onset of CLABSIs and catheter removal (OR 
1.10; 95% CI=1.02–1.20) were associated with higher death 
rates.66 Another similar study identified prolonged catheter 
in situ, pediatric ICU stay, and intravenous nutrition were 
significant prognosticators of peripherally inserted central 
catheter-related CLABSIs among hospitalized children.67
SSIs
SSIs (formerly termed “wound infections”) are still one of 
the most common adverse events that occur in hospitalized 
patients undergoing surgery or in outpatient surgical mea-
sures, regardless of the advances in preventive procedures.68 
SSI is the most common complication in postoperative surgi-
cal patients, associated with significant morbidity, high death 
rates, and financial stress on national budgets and individual 
patients.69–71 SSIs are defined as infections arising up to 30–90 
days after surgery in patients receiving an organ, group of 
cells, or device and affecting both the incisional site and 
deeper tissues around the surgery location.72,73
The type of surgery determines the proportion of SSIs. 
Between 2% and 36% of patients may develop SSIs, with 
the highest risk for orthopedic followed by cardiac and intra-
abdominal surgery.14,72,74,75 The length of hospital stay for 
patients with SSIs increases from 4 to 32 days as compared 
with patients with no post-surgical infections.76–78 Approxi-
mately 25% of patients with SSIs develop severe sepsis and 
shock and are moved to an ICU.65 SSIs cause statistically 
significant morbidity, mortality, and financial burdens for 
individuals and for communities.69–71,78
HCAIs are common following cardiac surgery, with a 
reported incidence rate of between 5.0% and 21.7%,79,80 
often accompanied with multiple organ failure and prolonged 
hospital stays, leading to increased mortality rates.79,80 The 
three most common locations for HCAIs after cardiac surgery 
are lungs, central venous catheters, and surgical sites.69 SSIs 
followed by cardiac surgery classically present with local-
ized cellulitis (erythema, warmth, and tenderness), purulent 
discharge, sternal instability, chest pain, and systemic upset 
with deep infections.81–83 SSIs are devastating for orthopedic 
patients as it is very difficult to rid the bones and joints of the 
infection.83 One Saudi Arabian study reported an incidence of 
SSIs in orthopedic patients of 2.55% (79 of 3,096 patients) 
with the most common pathogens being Staphylococcus 
species including MRSA (29.11%); Acinetobacter species 
(21.5%); Pseudomonas species (18.9%), and Enterococcus 
species (17.7%).84 Surgical wound contamination potentials, 
patients’ clinical conditions, type of surgery, and length of 
surgery were variables statistically significantly associated 
with SSIs and should be viewed as risk factors.85 The move-
ment and number of staff and the structural features of the 
operating theater also affect the incidence of SSIs.85,86 One 
study found that 73.33% cases of SSIs following orthopedic 
surgery were culture positive, and a total of 35 bacterial 
strains were isolated, among which 65.72% were Gram-
positive isolates and 34.28% were Gram-negative bacteria.87 
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About 68.6% of all bacterial isolates were resistant to cefu-
roxime used in the management of orthopedic SSIs. This 
study also found that diabetes mellitus, smoking, operations 
lasting more than 3 hours, the absence of antibiotic prophy-
laxis, and a history of previous surgery were positive risk 
factors associated with a significant upsurge in SSIs.87
SSIs comprise at least 14%–22.2% of all HCAIs for 
abdominal surgery88–90 and often lead to extended hospital-
ization and higher antimicrobial costs.71 The microorganisms 
generally involved in such SSIs include S. aureus, coagulase-
negative Staphylococci and Enterococcus spp., and E. coli.71 
S. aureus has been known to be a major cause of HCAIs for 
over 100 years.91 When first introduced, nearly all strains were 
susceptible to penicillin, but since its wide and often irratio-
nal use, S. aureus started to become resistant by producing 
β-lactamase enzyme.91 By 1960, 95% hospital variants of S. 
aureus were resistant.91,92 To help combat resistance, several 
new penicillins were developed to resist Staphylococcal 
β-lactamase, such as methicillin, oxacillin, cloxacillin, and 
flucloxacillin.91 However, within 1 year of methicillin being 
marketed in 1960, the first MRSA strain of S. aureus was 
reported in England.93 The MRSA strain represents 50% of 
HCAIs in the US and Europe and causes infections that are 
very difficult to manage because of their potential resistance 
to multiple antimicrobials.94–96 In one study, the incidence 
of SSIs was after gastrectomy in 11.3%, after colorectal 
surgery in 15.5%, after hepatectomy in 11.3%, and after 
pancreaticoduodenectomy in 36.9%.97 While the incidence 
of SSIs was higher in the absorbable stitching material than 
the silk group for all surgical procedures, the difference was 
not statistically significant. 97A Japanese study on abdominal 
surgery reported an overall SSI rate of 14.4%. The SSI rates 
in the suture-less, Vicryl, and silk groups were 4.8%, 14.8%, 
and 16.4%,88 respectively, again with no statistically signifi-
cant differences between the groups. In colorectal surgery, 
the SSI rate in the polyglactin 910 (absorbable, synthetic, 
usually braided suture; VicrylTM) group was 13.9%, which 
was statistically significantly lower than that of the silk 
group (22.4%; P=0.034). The incidence of deeper SSIs in 
the Vicryl group, including deep incisional SSIs (ISSIs) and 
organ/space SSIs (OSIs), was statistically significantly lower 
than that in the silk group (P=0.04).88 The SSI rates did not 
differ among the suture types overall in gastric surgery or in 
appendectomy.98 A US study of pediatric patients found that 
while this was only 2.5% of the caseload, colorectal surgery 
contributed to 7.1% of the SSIs.98 The SSI rates of all types 
of colorectal surgery were 5.9% (ISSIs: 3.2%; OSIs: 2.7%) 
with the uppermost being total abdominal colectomy (11.4%) 
trailed by partial colectomy (8.3%) and colostomy closure 
(5.0%).98 Inflammatory bowel diseases caused the topmost 
health problems in a comparison of all colorectal diagnosed 
diseases (24.9%; ISSIs: 22%; OSIs: 28.6%). Hirschsprung’s 
disease (14.2%; ISSIs: 15.4%; OSIs: 12.8%) and anorectal 
malformations (12.4%; ISSIs: 17.6%; OSIs: 6.4%) were the 
next major group in colorectal diseases.98 Finally, a study uti-
lizing univariate analysis defined 13 statistically significantly 
variables related to SSIs. Those were patients aged over 60 
years, lower functional status, diabetes mellitus, congestive 
heart failure, immunocompromising disease, anticancer 
medications, immunosuppressive agents, impaired immune 
system, open cholecystectomy, laparotomy, an American 
Society of Anesthesiologists score above 2, drain insertion, 
and dirty wound.99 Using multivariate regression analysis, 
this study also found that immunosuppressive agents (OR 
=2.5, 95%, CI =1.099–143.443), open cholecystectomy (OR 
=2.25, 95% CI =2.242–40.109), and contaminated wound 
(OR =2.179, 95% CI =3.80–20.551) were statistically sig-
nificantly linked with SSIs.99
Catheter-associated urinary tract 
infections (CAUTIs)
Internationally, UTIs are the most common HCAIs and one 
of the top ranking microbial infections, representing around 
40% of HCAIs, with significant consequences for morbidity 
and mortality and substantial financial implications.14,99,100 
Although CAUTIs are typically benign, some patients have 
potentially pathogenic virulent bacteria but are asymptom-
atic, and these patients were associated with a three-times 
higher mortality than in non-bacteriuric patients.101,102 Multi-
variate analysis indicates the risk factors for CAUTIs includ-
ing prolonging the duration of the catheter, female sex, older 
age, diabetes mellitus, the absence of systemic antibiotics, 
catheter insertion outside the operating room, and a breach in 
the closed system of catheter drainage.101,103 The rate of CAU-
TIs has been estimated to be about 5% per day, regardless of 
the duration of the indwelling catheter, with E. coli being the 
main infecting pathogenic microorganism, although a wide 
spectrum of other microorganisms were identified, including 
eukaryotic fungus.104,105 The repetitive inappropriate admin-
istration of antimicrobials often leads to greater bacterial 
resistance. CAUTIs habitually lead to biofilm formation on 
both the extraluminal and intraluminal portal catheter surface, 
largely from extraluminal microorganisms.106–108 The biofilm 
defends microbes from both antimicrobials and host defense 
mechanisms.109 Although morbidity from CAUTIs with short-
term catheter use is limited if catheters are appropriately 
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inserted and cleaned, in patients with long-term indwelling 
catheters, fever from CAUTIs is common with a frequency 
fluctuating from one per 100 to one per 1,000 catheter days.105 
Patients in institutional care with long-term indwelling 
catheters have a greater risk for the presence of pathogenic 
microorganisms and other urinary tract diseases than those 
without catheters.105 One meta-analysis found that CAUTIs 
were linked with statistically significantly higher death rates 
(OR =1.99; 95% CI =1.72–2.31; P<0.00001; I2=54%; eight 
studies; 62,063 patients) and days in the ICU (weighted mean 
difference of +12 days; 95% CI =9–15; P<0.00001; I2=96%; 
seven studies; 13,011 patients) and hospital (mean difference 
+21 days; 95% CI =11–32; P<0.0001; I2=98%; five studies; 
10,183 patients).110 An Australian health care-associated 
urinary tract infection (HCAUTI) non-concurrent cohort 
study carried out for 4 consecutive years found that patients 
had an extra 4 days (95% CI =3.1–5.0 days) of hospitaliza-
tion.111 This study further reported that the infection rate was 
statistically significantly minimized utilizing a Cox regres-
sion model (HR =0.78; 95% CI =0.73–0.83) when patients 
were released from the hospital.111 HCAUTIs very rarely 
cause death (HR =0.71; 95%CI =0.66–0.75), especially in 
large hospitals when compared to other health care institutes, 
even when compared with age and sex (HR =0.74; 95% CI 
=0.69–0.78), although elderly patients more often died (HR 
=1.40; 95% CI =1.38–1.43).111
vAP
The death risk for patients in the ICU is not only because 
of their original illness but often because of HCAIs.2,54,112 
Pneumonia is the second commonest HCAI in ICUs, 
affecting more than one-quarter of patients.113,114 Around 
86% of HCAIs are associated with motorized automatic 
ventilation and VAP.113 Between 9% and 27% of patients 
with assisted ventilation develop this kind of pneumonia, 
and VAP has been identified internationally as a potential 
major cause of death.114 The average critical time to develop 
VAP following endotracheal intubation and mechanical 
ventilation was 2–3 days.115 Patients usually develop a 
fever, altered bronchial sounds, white blood cell counts 
reduced, changes in sputum, and causative organisms are 
often identified.116–121 A US study found a range of VAP of 
between 1.2 and 8.5 per 1,000 ventilator days122 although an 
international group reported a much higher occurrence of 
VAP of 13.6/1,000 ventilator days.123 In Asian countries, a 
different picture of 3.5–46 infections/1,000 ventilator days 
emerges,124 with a very high incidence rate in India of 40.1 
per 1,000 ventilator days.125 The initial 5 days of mechanical 
ventilation is the most critical time for the development of 
VAP, with a mean duration of 3.3 days between intubation 
and the development of VAP.119–126 Another recent Indian 
study reported that non-fermentative Gram-negative 
bacilli127 were the predominant organisms, followed by 
Pseudomonas and Klebsiella genus. In this study, S. aureus 
reduced in prevalence from 50% to 34.9% between 2011 
and 2013, but between 2012 and 2013 vancomycin-resistant 
Enterococci increased from 4.3% to 8.3%, while methicil-
lin resistance among S. aureus exceeded 50% in 2013. In 
addition, an upwavard trend in resistance by Pseudomonas 
genus was observed for piperacillin-tazobactam, amikacin, 
and imipenem. The incidence of non-fermenters’ resis-
tance continued to be very high except for amikacin and 
imipenem (33.1%) and polymyxin-B (2.4%).127 A study at 
Chonnam National University Hospital in South Korea of 
the transtracheal aspirates or bronchoalveolar lavage of 
patients suffering from VAP found that S. aureus (44%) 
was the most frequently detected causative microorganism 
followed by A. baumannii (30%), P. aeruginosa (12%), 
Stenotrophomonas maltophilia (7%), K. pneumoniae (6%), 
and Serratia marcescens (2%).128 In addition, S. aureus was 
found as MRSA and 69% of Acinetobacter baumannii were 
imipenem-resistant.128 No statistically significant variance 
was observed in the imipenem-resistant A. baumannii128 
between the earlier and late VAP-related study groups (73% 
[8/11] vs 67% [14/21], P=1.000).128 In this study, 67% of 
K. pneumoniae was ESBL-positive.128 VAP was frequently 
linked with substantially increased morbidity, including 
prolonged ICU and hospitalization, and higher ventilator 
days and health care costs.129
In the UK and the Republic of Ireland, a European 
study of HCAIs connected with respiratory infection found 
a prevalence rate of 7.59%. Among these HCAIs, 15.7% 
were pneumonia, and 7% were lower respiratory tract infec-
tions other than pneumonia (LRTIOP).130 Around 21% of 
patients in both the groups were having artificial ventila-
tion, which was much higher when compared to the rest of 
the patients with HCAIs. MRSA was the principal invading 
microorganism for both pneumonia and LRTIOP. Although 
the patients with LRTIOP suffered more from C. difficile-
induced diarrhea than pneumonia, this was not statistically 
significant.130 A recent Chinese study reported that 14.94% 
(895) of inpatients acquired a LRTI which prolonged their 
hospital stay and increased the costs per individual case by 
US$2,853.93.131 Another study revealed that 9.6% of patients 
developed HCAIs, of which respiratory tract infections 
were the highest at 65.8%.132 The most frequently identified 
 respiratory pathogen was Gram-negative Acinetobacter spe-
cies (40.4%), and among these 21% were MDR.132
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A significant number of patients develop pneumonia after 
surgery which includes both hospital-acquired pneumonia 
(pneumonia developing 48–72 hours after admission) and (as 
discussed above) VAP (pneumonia developing 48–72 hours 
after endotracheal intubation).133 Postoperative pneumonia 
has been described as one of the leading consequences of 
all types of surgery with a high incidence of morbidity and 
mortality.134 It increases hospital stays on an average of 7–9 
days and increases health care costs from US$12,000 to 
US$40,000.114,135,136
HCAIs
HCAIs are a major safety concern for both health care pro-
viders and patients. They continue to escalate at an alarm-
ing rate, especially in emerging economies, with infection 
rates 3–20 times higher than in high-income countries.1,2,137 
HCAIs increase morbidity, mortality, length of hospital 
stays, and costs;138–140 therefore, more research and changes 
in practice are needed to ensure hospital safety and prevent 
HCAIs.32,141–143 The annual costs for HCAIs alone in the 
USA are between US$28 and US$45 billion, but with even 
this amount of spending, 90,000 lives are still lost per year: 
HCAIs are among the top five killers in the USA.14,144–147 The 
WHO advocates that effective hand hygiene is the single 
most important practice to prevent and control HCAIs, which 
form colonies with MDR microbes.1,2,148,149 Several studies 
report that a simple and straightforward process, taking only 
a few seconds to clean hands with an alcohol-based hand rub 
helps prevent HCAIs and save lives, reduce morbidity, and 
minimize health care costs.150,151 However, factors such as 
the availability of alcohol-based hand rubs and up-to-date 
knowledge of the importance of hand washing hinder good 
practice in hand hygiene. For example, an Australian observa-
tional study of community nurses highlighted poor practices 
of hand hygiene in comparison with a standard protocol.152
The WHO promotes and advocates that all health care 
workers (HCWs) must wash their hands before touching a 
patient, before clean/aseptic procedures, after body fluid 
exposure/risk, after touching a patient, and after touching 
patient surroundings.153 The Center for Disease Control 
and Prevention has developed a comprehensive plan and 
guidelines for the prevention of HCAIs which covers basic 
infection prevention and control (IPC); antibiotic  resistance; 
device- and procedure-associated infections; disease/
organism-specific infections; and guidance for health work-
ers working in specific settings.154 This guidance, like that 
of the WHO and the UK Royal College of Nursing (RCN) 
also emphasizes the importance of hand washing.153–155 The 
RCN also promotes and advocates that all health care profes-
sionals must receive compulsory “infection control training 
as part of their induction and on an ongoing annual basis. 
It is particularly important that knowledge and skills are 
continually updated.”155 Multiple research studies indicate 
that policy changes and the adoption of novel multifactorial, 
multimodal, multidisciplinary strategies offer the greatest 
possibility of success in terms of hand hygiene improvement 
and the reduction of HCAIs.156–167
Instigating best practice in health care stems “from 
a response to factors that are outside a purely scientific 
understanding of infection and not simply understood as a 
deficit in knowledge.”168,169 Good practice for infection pre-
vention among HCWs can be ensured through compliance 
to IPC guidelines.168 Specific individuals acting as “change 
champions” can act as arbitrators or negotiators, contribut-
ing to changing behaviors and implementing best practice 
to ensure patient safety.168–171 This calls for educational 
interventions that reflect the philosophies, principles, and 
community understanding of dirt and infection.169 An edu-
cational intervention involving 4,345 health professionals 
in three public hospitals in the USA successfully improved 
hand hygiene immensely with the use of alcohol hand rub. 
Nurses, physicians, and allied HCWs improved from 14% to 
34%, 4.3% to 51%, and 12% to 44%, respectively.172 Other 
studies also highlight how behavior change around hand 
washing can result from educational interventions.149,151,172 
Health professionals must protect themselves with barriers 
for example, gloves, gowns, face masks, protective eyewear, 
and face shields,173 to decrease the work-related transmis-
sion of microorganisms. Regular use of personal protective 
equipment (PPE)173 devices protects both the professional 
and the patient from potentially infectious body fluids.173 
Nevertheless, the use of PPE does not confirm 100% pro-
tection,174 for example, needlestick injury can breach PPE, 
and, in many occasions, issues might go unrecognized 
which might cause a dangerous health hazard including 
hepatitis B or HIV.175
Respiratory microorganisms, for example, influenza 
virus, Bordetella pertussis, Haemophilus influenzae, Neis-
seria meningitidis, and Mycoplasma pneumoniae, severe 
acute respiratory syndrome-associated coronavirus, Group 
A Streptococcus, adenovirus and rhinovirus, and tubercular 
bacilli176 are easily dispersed through droplets (particles ≤5 
µm in size) in closed health care settings and often cause 
endemics and epidemics.176 PPE, vaccines, and drugs are 
the main measures to prevent and control such infections.177 
This includes national annual campaigns such as requiring all 
health professionals to have a flu vaccine. Multiple research 
studies have found that poor cleaning of hospital surfaces is a 
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major source of HCAIs because of the transmission of many 
dangerous microorganisms such as MRSA, vancomycin-
resistant Enterococcus spp. (VRE), C. difficile, Acinetobacter 
spp., and norovirus.178–182 Meticulous cleaning of hospital 
surfaces is therefore vital to maintain standards and reduce 
the risk of HCAIs.183 Several studies conclude that ultraviolet 
devices and hydrogen peroxide vapor technologies success-
fully eradicate potentially dangerous hospital microorgan-
isms adhering to the surfaces in ward or patient rooms.183–186 
Furthermore, hydrogen peroxide vapor efficiently sterilizes 
and sanitizes all clinical areas where potentially dangerous 
microbial MDR microorganisms and spores were suspected 
to be present.187
Conclusion
In the early to mid-19th centuries in both Europe and USA, 
thousands of young women died from puerperal sepsis and 
fever, the diseases rampant in the charity maternity clinics 
of the time188 and, due to the efforts of (among others) Dr 
Ignaz Phillip Semmelweis and Dr Oliver Wendell Holmes, the 
fight against puerperal fever was won and it was confirmed 
that HCAIs were transmitted via the hands of HCWs.188–192 
Despite the development of many hi-tech methods, hand 
washing with soap and water or alcohol rub is still the 
most important means of maintaining personal hygiene and 
preventing HCAIs.192 However, due to the rise of antibiotic-
resistant bacteria and a reluctance of some HCWs to imple-
ment best practice infection control, HCAIs remain one of 
the biggest causes of death in most countries. Therefore, it 
is essential that strategic, policy, and education initiatives 
continue to focus on managing and controlling such (pre-
dominantly needless) infections.
Limitations of the study
The topic of HCAIs is a very broad issue, and it has therefore 
not been possible to cover all aspects of HCAIs in one paper; 
hence, we have been selective in selecting key aspects of the 
current debate.
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